Hofseth Biocare ASA: HBC's ProGo® has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago

16 Jul 2025 08:00 CEST

According to the judges, the winning factors placing ProGo® well ahead of the
competition are its unique ability to activate GLP-1 and GIP receptors, coupled
with its unrivalled sustainability credentials including Upcycled Certified by
WFCF (Where Food Comes From). Most significantly, these benefits are supported
and evidenced through two clinical studies demonstrating weight loss with
ProGo®.

ProGo® Bioactive Peptides optimize the metabolism of glucose and fat to improve
energy levels and weight profile. Their novel mode of action extends the
healthspan of all ages to allow a more active lifestyle for longer. As a result,
ProGo® is gaining increasing attention for consumer health and medical nutrition
applications.

https://www.nutraingredients-usa.com/Article/2025/07/15/nutraingredients-usa-
announces-2025-award-winners/

https://www.linkedin.com/feed/update/urn:li:activity:7350776392273281024

For further information, please contact:
James Berger, Chief Commercial Officer of Hofseth BioCare ASA
Phone: +41 799501034
E-mail: jb@hofsethbiocare.com (mailto:jb@hofsethbiocare.com)

About Hofseth BioCare ASA:
Hofseth BioCare is a Norwegian consumer and pet health company founded on the
core values of sustainability, optimal utilization of natural resources and full
traceability. It upcycles the side streams of the salmon industry by taking
fresh filleted salmon and converting it from a waste product into ingredients to
improve human and pet health. These ingredients are ProGo®, a mix of bioactive
peptides and collagen, OmeGo®, a whole salmon oil, with all the fatty acid
fractions contained in fish, and CalGo® / NT-II(TM) salmon bone powder
containing calcium hydroxyapatite and undenatured collagen for bone and joint
health.

HBC places scientific evidence at the forefront which has led to important
academic partnerships and the identification of unique health benefits. This
includes the demonstration of improved iron metabolism by boosting the body's
ability to take up and use iron resulting in increased energy and vitality with
ProGo® as well as the activation of the GLP-1 receptor with fat reduction in
overweight adults. OmeGo® has shown important immune health benefits including
recovery from viral infection and improved respiratory health and sleep in
adults troubled by particulate matter pollution. Finally, CalGo® has shown both
bone and joint health benefits to support healthy ageing and active lifestyles.
This work has also resulted in the granting of a number of patents protecting
these discoveries. It has also led to the discovery of potential therapeutics
and HBC has spun out a biotech-focused company, HBC Immunology (HBCI). HBCI has
raised external finance, and the lead program is in prostate cancer followed by
ovarian cancer. A separate molecule is targeted as an oral, steroid-sparing
therapy for asthma.

More information:
Access the news on Oslo Bors NewsWeb site